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The heat shock protein 90 (Hsp90) folding machinery is essential for the maturation of
nascent polypeptides into their biologically active three-dimensional-structures and for the
rematuration/clearance of misfolded proteins that form under cellular stress.1–3 As a
prosurvival chaperone, Hsp90 overexpression is commonly observed in transformed cells,
which is required to sustain the hostile tumor micro-environment associated with nutrient
deprivation and hypoxia. Pharmacological inhibition of Hsp90 has been shown to induce the
degradation of oncogenic proteins associated with all six hallmarks of cancer that rely upon
Hsp90.4–8 Consequently, Hsp90 represents a highly sought after target for the treatment of
cancer. In fact, 17 small molecules that bind competitively to the N-terminal ATP-binding
pocket are under clinical evaluation against various cancers.9,10 However, heat shock factor
1 (HSF-1), the master regulator of the pro-survival heat shock response also binds Hsp90.
Ultimately, Hsp90 N-terminal inhibition results in HSF-1 release, and upon phosphorylation,
trimerizes and translocates to the nucleus wherein it binds the heat shock elements to
activate the pro-survival, heat shock response (HSR). The HSR serves to expand the cellular
buffering capacity and to assist in the maturation of mutated and oncogenic substrates.11
This concomitant heat shock response is detrimental to the treatment of cancer and may lead
to drug resistance and tumor metastasis.12 Recent studies have demonstrated that allosteric
modulation of the Hsp90 C-terminus can separate the pro-survival heat shock response from
pro-apoptotic, client protein degradation.13–20 Two classes of small molecules derived from
novobiocin 1, (Figure 1) the first identified Hsp90 C-terminal inhibitor, were discovered via
the structure-activity relationship studies. KU-32 (2), which lacks a 4-hydroxyl, the 3’-
carbamate, and contains an acetamide in lieu of a prenylated benzamide, represents a lead
compound that induces the heat shock response at concentrations much lower than that
needed for client protein degradation.2,21 Consequently, this class of analogues has been
evaluated as neuroprotective agents to refold protein aggregates.22–24 In contrast, KU-174
(3) contains a biarylamide side chain in lieu of the acetamide, and induces Hsp90 client
protein degradation without induction of the heat shock response.25–26 Therefore, this class
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of novobiocin analogues manifests optimal properties for the treatment of cancer, as no HSR
is observed with such compounds.
Recently, a second generation of novologues that contains a scaffold that mimics KU-32
was identified, and biological evaluation against primary sensory neurons showed these
molecules to possess enhanced neuroprotective properties.27 Novologue 4 contains a 3-
trifluoromethylphenyl ring in lieu of the coumarin lactone present in novobiocin and
incorporates the acetamide onto the flexible ethylene linker to maintain hydrogen-bonding
interactions with the Hsp90 C-terminal binding pocket. As shown during the discovery and
development of novobiocin-based Hsp90 C-terminal inhibitors, restoration of the benzamide
side chain onto KU-32 transforms the molecule from manifesting neuroprotective activity
into one that serves as an anti-cancer agent. Therefore, we hypothesized that replacement of
the acetamide present in novologue 4 with a biarylamide should also transform this
novologue into an anti-proliferative agent (5a).
As shown in Scheme 1, retrosynthesis of compound 5a (and related analogues) was
envisioned for construction via noviosylation of phenol 7 by activated noviose carbonate, 6.
Intermediate 7 could be assembled via an amide coupling reaction between amine 8 and acid
chloride 9, followed by hydrogenolysis. As reported previously,27 the synthesis of amine 8
could be achieved from 2,4-dihydroxybenaldehyde through phenol protection, Suzuki
coupling, a Henry reaction, and reduction of the corresponding α,β-unsaturated nitro styrene.
Synthesis of these novologues commenced via selective phenol protection of 2,4-
dihydroxybenaldehyde (10) with benzyl bromide. The resulting benzyl ether was converted
to trifluoromethanesulfonate 11, in the presence of trifluoromethanesulfonic anhydride and
triethylamine. Subsequent Suzuki coupling with commercially available aryl boronic acids
(phenyl, m-CF3, m-Cl, m-F and m-OMe) was employed to generate the respective biaryl ring
systems, 12a–e. These boronic acids were selected based on prior studies that suggested the
inclusion of electronegative substituents at the meta-position of the B-ring exhibit favorable
interactions with Lys539 in the Hsp90 C-terminal binding pocket.27
Benzaldehydes 12a–e were subjected to a Henry reaction to afford the corresponding
nitrostyrenes, 13a–e. Subsequent lithium aluminum hydride reduction of the nitrostyrenes to
the corresponding amines, followed by acylation with benzoyl chlorides 9a–e gave the
benzyl ether containing benzamides, which upon hydrogenolysis produced phenols 7a–i.
Preparation of the novologues required noviosylation of phenols 7a–e, which occurred upon
treatment with the trichloroacetimidate of noviose carbonate 6 in the presence of catalytic
boron trifluoride etherate, followed by solvolysis of the cyclic carbonate with methanolic
ammonia to generate the desired products, 5a–e, in good yields.
In addition, novologues 14a–i were synthesized to investigate prior observations that
suggested the replacement of noviose with amines could further increase inhibitory activity
and solubility.28–31 Therefore, Mitsunobu etherification of phenols 7a–i with 1-methyl-4-
hydroxypiperidine was performed to yield the amino containing novologues, 14a–i.
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Upon construction of the library, these novologues were evaluated for antiproliferative
activity against two breast cancer cell lines: SKBr3 (estrogen receptor negative, HER2 over-
expressing breast cancer cells) and MCF-7 (estrogen receptor positive breast cancer cells).
As shown in Table 1, the novologues manifested anti-proliferative activity against both
breast cancer cell lines. Novologues containing a piperidine ring were shown to exhibit
greater activity than their noviose containing counterparts (14a–e vs 5a–e), which is
consistent with prior studies on novobiocin.28 Although substitutions on the benzamide side
chain were beneficial to anti-proliferative activity, 4-Cl (5e) and 4-methoxy (5c) were better
than 4-t-butyl (5d) for the compounds containing noviose. However, compounds containing
the piperidine ring manifested better activity when 4-t-butyl (15c) or 4-Cl (15d) were
present, compared to the 4-methoxy derivative (15b). Substitutions on the B ring did not
produce significant differences in anti-proliferative activity, however, as predicted, the
inclusion of an electronegative atom (F, Cl and CF3) at the meta-position of the B-ring was
most active. As hypothesized, all the novologues were more active than the parent,
acetamide-containing, neuroprotective compound 4.
In order to gain further insight into this class of compounds, a comparison between the anti-
proliferative activities manifested by novobiocin-derived inhibitors and these novologues
was performed. Although the benzamide side chain is attached to a freely rotating ethylene
linker in novologues 5a and 14a, they manifested similar activity to novobiocin derivatives
16 and 17, suggesting that this new scaffold can serve as a surrogate for the coumarin ring
system. More importantly, the entropic penalty introduced by incorporation of the ethylene
linker appears to be compensated by interactions provided by incorporation of the
trifluorophenyl ring. Alternatively, the rigid coumarin ring system may not be optimal for
binding interactions.
To confirm that Hsp90 inhibition was responsible for the observed anti-proliferative
activities manifested by these novologues, Western blot analyses of several Hsp90
dependent client protein levels were examined in MCF-7 cell lysates treated with 14a.32 As
shown in Figure 2, Her2, Raf-1 and p-Akt, all of which are well-validated Hsp90-dependent
client proteins, were degraded in a concentration-dependent manner, while non-Hsp90-
dependent actin levels remained constant. In addition, Hsp90 levels remained unchanged,
indicating that these novologues bind the Hsp90 C-terminus.33–36
In conclusion, a library of benzamide-containing novologues was designed, synthesized and
evaluated against two breast cancer cell lines. Initial structure-activity relationships for the
amide appendage were elucidated and novologue 14a was shown to exhibit lead-like
activity. Western blot analyses demonstrated these compounds to manifest anti-proliferative
activity through Hsp90 inhibition. Replacement of the acetamide side chain on the
novologue scaffold with a benzamide side chain successfully transformed this class of
neuroprotective agents into molecules that exhibit anti-proliferative activity. Further
structure-activity relationship studies on this novologue scaffold are currently underway and
will be reported in due course.
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Hypothesis for the design of cytotoxic novologues.
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Western blot analysis of Hsp90-dependent client proteins from MCF-7 breast cancer cell
lysate upon treatment with 14a. Concentrations (in µM) were indicated above each line.
Geldanamycin (G, 0.5 µM) and dimethylsulfoxide (D, 100%) were employed as positive and
negative controls.
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Retrosynthesis of cytotoxic novologues.
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Synthesis of phenol 7a–e.
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Synthesis of cytotoxic novologues.
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